UNSPSC 51262909: Bopindolol fumarate

This classification denotes an adrenergic beta-antagonist C23H28N2O3.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GM76OF8LS3, chemically known as 2-propanol, 1-((1,1-dimethylethyl)amino)-3-((2-methyl-1h-indol-4-yl)oxy)-, 2-benzoate, 2-butenedioate (1:1), but more generally known as bopindolol fumarate, which bears US NIH Compound Identifier 13302095. Most nations, for tariff and trade purposes, schedule bopindolol fumarate under HS 29339990 and SITC 51577.

As of Q4 2014, BOPINDOLOL FUMARATE remains US FDA's Preferred Term for this commodity. SMILES: CC1CC2C([NH]1)CCCC2OCC(CNC(C)(C)C)OC(=O)C3CCCCC3.C(=C/C(=O)O)\C(=O)O.

UNSPSC 51262909 Bopindolol fumarate is a Commodity code that nominally names a specific beta-blocker pharmaceutical, but recent state and local opportunities tagged under this code show little alignment with the code's stated product. The Seminole County, Florida procurement (IFB 60459723LAS) sought Naloxone and Safe Drug Deactivation Systems, while the Texas Health and Human Services Commission RFI (HHS0017013) sought vendor capabilities for a direct-to-manufacturer prescription program — neither of which involves bopindolol fumarate. State and local procurement offices appear to be using this code as a catch-all for pharmaceutical and drug-related products or services, rather than restricting it to the narrowly defined pharmaceutical substance the code nominally represents. The issuing bodies include county health departments and state health agencies managing public health and substance-abuse initiatives, though the sample is too small to establish a clear pattern of repeat buyers.

Geographic activity centers on Florida and Texas, based on the two recent opportunities identified. The Seminole County IFB (due July 26, 2023, with quarterly delivery requirements to Sanford, Florida) represents a consumables-procurement model for community health support, while the Texas HHS Commission RFI (response deadline April 3, 2026) represents upstream market intelligence gathering on pharmacy contracting structures. Neither opportunity is substantively related to bopindolol fumarate procurement, suggesting that the code's use at the state and local level may be inconsistent with its intended scope or that the code is being misapplied in procurement systems. Business development professionals should verify whether opportunities actually tagged under this code align with their service or product offerings before investing pursuit effort.